IDEAYA Biosciences (IDYA) Cash & Current Investments (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Cash & Current Investments data on file, last reported at $671.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 35.58% year-over-year to $671.2 million; the trailing twelve-month figure through Mar 2026 stood at $671.2 million (down 35.58% YoY), and the FY2025 full-year result was $639.4 million, down 5.46% from the prior year.
• Cash & Current Investments rose to $671.2 million in Q1 2026, from $639.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.0 billion in Q1 2025 to a low of $252.6 million in Q1 2022.
• A 5-year average of $582.7 million and a median of $639.4 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 105.84% in 2024 and plunged 35.58% in 2026, its largest moves.
• Tracing IDYA's Cash & Current Investments over 5 years: stood at $364.8 million in 2022, then surged by 43.93% to $525.1 million in 2023, then climbed by 28.79% to $676.3 million in 2024, then decreased by 5.46% to $639.4 million in 2025, then climbed by 4.98% to $671.2 million in 2026.
• Business Quant data shows IDYA's Cash & Current Investments at $671.2 million in Q1 2026, $639.4 million in Q4 2025, and $786.9 million in Q3 2025.